Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00781586 · ClinicalTrials.gov registry record · Phase 4
Efficacy of ONE A DAY Weightsmart Advanced Versus Caffeine and Placebo on Energy Expenditure, Thermogenesis and Perceived Energy Levels in Women.
A Phase 4 study of Energy Expenditure, sponsored by Bayer.
- Completed
- Registry status
- Phase 4
- Development phase
- 22
- Enrollment target
- 1
- Study location
NCT00781586: Completed Phase 4 study of Energy Expenditure, sponsored by Bayer.
NCT00781586 is a Phase 4 study of Energy Expenditure that has completed, run by Bayer. The registered enrollment target is 22 participants, below the 91-participant average among 6 other Energy Expenditure trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00781586, a Phase 4 study of Energy Expenditure, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 22 participants
- Enrollment target
- 1
- Study location
Study Summary
The study is considered research because efficacy (how well a drug works) information is needed in healthy, 25-45 year-old, female subjects with moderate caffeine intake. The investigational product is available in the United States without a prescription (over-the-counter) as a nutritional supplement. The purpose of this study is to assess whether One-A-Day Weightsmart Advanced is safe and can increase metabolism and perceived energy in female subjects compared with caffeine or placebo (inactive drug). Participation in this study will last approximately 4 weeks and require about 4 outpatient visits to St. Luk's-Roosevelt Hospital Center. About 21 subjects are expected to participate in this study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Caffeine
- DIETARY_SUPPLEMENT One-A-Day Weight S.A. (Multi-Vitamins, BAY94-9350)
Study Locations (1)
New York
- - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2007-10-02 |
| Est. Completion | 2008-04-21 |
| Phase | Phase 4 |
What the finished NCT00781586 record still lists
NCT00781586 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 91-participant average among 6 other Energy Expenditure trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Energy Expenditure appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00781586 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00781586 about?
NCT00781586 is a clinical study titled "Efficacy of ONE A DAY Weightsmart Advanced Versus Caffeine and Placebo on Energy Expenditure, Thermogenesis and Perceived Energy Levels in Women.". The study is considered research because efficacy (how well a drug works) information is needed in healthy, 25-45 year-old, female subjects with moderate caffeine intake. The investigational product is available in the United States without a prescription (over-the-counter) as a nutritional suppleme...
What is the current status of trial NCT00781586?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 22 participants. The study started on 2007-10-02. Estimated completion is 2008-04-21.
What conditions does trial NCT00781586 study?
This clinical trial studies the following conditions: Energy Expenditure.
What interventions are being tested in trial NCT00781586?
The interventions under investigation include: Placebo (DRUG), Caffeine (DRUG), One-A-Day Weight S.A. (Multi-Vitamins, BAY94-9350) (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00781586?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00781586 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Energy Expenditure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals
RECRUITING · Phase 2
-
GENESIS: Genotype Guided - Natriuretic Peptides - Cardiometabolic Health Study
RECRUITING · NA
-
Studying Phenotypic Risks for Obesity and Underlying Traits in Young Infants
RECRUITING
-
Effect of Naringenin and Beta Carotene on Energy Expenditure
COMPLETED · NA
-
Quantifying the Persistence of Metabolic Adaptation and Weight Regain Following Extreme Weight Loss
COMPLETED
-
Breakfast and Muscle Health in Children
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI